GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Organon Co.
Organon, spun off from Merck, focuses on women's health and the production of biosimilars and established brands. Its share price reflects the stable cash flows from these products, but also the challenges associated with finding new growth drivers after the split.
Share prices of companies in the market segment - Pharma women
Organon, spun off from Merck, focuses on women's health and biosimilars. We classify it as part of the women's pharmaceuticals sector, and the chart below shows the overall dynamics of this market, as well as the stability of revenue from established brands.
Broad Market Index - GURU.Markets
Organon is a global pharmaceutical company focused on women's health, biosimilars, and generics. Its unique niche makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Organon compares to the overall market dynamics.
Change in the price of a company, segment, and market as a whole per day
OGN - Daily change in the company's share price Organon Co.
The daily price change of Organon, a pharmaceutical company focused on women's health, reflects the stability of its drug portfolio. Change_co measures moderate volatility, typical of companies with mature products. This metric is important for formulas on System.GURU.Markets that analyze defensive qualities and dividend policies in the pharmaceutical sector.
Daily change in the price of a set of shares in a market segment - Pharma women
Organon & Co. is a pharmaceutical company. This chart shows the average daily volatility of the sector. Comparing it to OGN, which focuses on women's health and biosimilars, helps us understand its unique and relatively stable risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
Organon, a spinoff from Merck, is a global pharmaceutical company focused on women's health. The healthcare sector is considered relatively defensive. The chart below shows general market fluctuations, which can be used to assess Organon's response to economic challenges.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Organon Co.
Organon, a spinoff from Merck, is now a company focused on women's health and biosimilars. Its year-over-year growth reflects the stable demand for its products and its strategy to fill this important niche in the pharmaceutical industry.
Annual dynamics of market capitalization of the market segment - Pharma women
Organon & Co., spun off from Merck, focuses on women's health and its portfolio of established brands. Its goal is to prove its ability to grow as a standalone company. The chart will show how the market views its unique strategy and ability to generate cash flow from its mature portfolio.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Organon, focused on women's health and biosimilars, is a defensive pharmaceutical company. Demand for its products is stable and driven by demographic rather than economic factors. The company's share price performance reflects the predictability of its business, making it attractive to conservative investors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Organon Co.
The market capitalization of Organon, a pharmaceutical company focused on women's health (spinned out of Merck), depends on its product cycle. The monthly fluctuations on the chart reflect sales of its contraceptives and other drugs, as well as stable revenue from its portfolio of well-known but outdated drugs.
Monthly dynamics of market capitalization of the market segment - Pharma women
Organon & Co. has carved out a unique niche in the pharmaceutical industry, focusing on women's health and biosimilars. The company's growth is driven by demand for its key drugs and the successful launch of new products. The pharmaceutical sector dynamics chart allows you to compare Organon's strategy with overall industry trends and assess its market potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Organon & Co. is a global pharmaceutical company focused on women's health and biosimilars. The healthcare sector is considered "defensive." Amid market fluctuations, as shown in the chart, Organon's performance may be more stable. Its success is determined by sales of key products and the launch of new drugs, not by the economic climate.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Organon Co.
Shares of Organon & Co., a pharmaceutical company focused on women's health, reflect stable demand for its products. Weekly price movements respond to sales reports, patent news, and general trends in the healthcare sector. The chart below shows how short-term market fluctuations affect the valuation of this diversified portfolio.
Weekly dynamics of market capitalization of the market segment - Pharma women
How typical are Organon & Co.'s performance indicators for the pharmaceutical sector? This chart compares the weekly stock price movements of this women's health company to the industry average. This helps us understand whether its price performance is more stable than that of biotech startups due to its diversified portfolio, or whether it follows general trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Organon & Co. is a pharmaceutical company specializing in women's health and biosimilars. This chart compares its weekly performance to the broader market. It helps understand whether its focus on stable, albeit slower-growing, markets results in less volatility than the S&P 500.
Market capitalization of the company, segment and market as a whole
OGN - Market capitalization of the company Organon Co.
Organon & Co.'s market capitalization reflects how investors view its focus on women's health. Having spun off from Merck, the company now owns a portfolio of well-known, but no longer new, drugs and biosimilars. The chart reflects investors' assessment of this diversified portfolio's ability to generate stable cash flow.
OGN - Share of the company's market capitalization Organon Co. within the market segment - Pharma women
Organon & Co. is a global pharmaceutical company focused on women's health, including biosimilars and established brands. Its share of its sector market capitalization reflects its unique specialization and diversified portfolio. The chart shows how investors view its growth strategy in women's health and the stability of revenue from other products.
Market capitalization of the market segment - Pharma women
The graph illustrates the total value of pharmaceutical companies focused on women's health. Organon & Co., after spinning off from Merck, became the global leader in this niche. The dynamics in the chart show how the market values this important, yet often overlooked, healthcare segment.
Market capitalization of all companies included in a broad market index - GURU.Markets
The chart below visualizes the market value of a focus on women's health. The market capitalization of Organon & Co., a spinoff of Merck, is the valuation of its portfolio of drugs in contraception and gynecology. The line shows how this narrow specialization is finding its significant and unique niche in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
OGN - Book value capitalization of the company Organon Co.
This is a valuation of the assets of Organon & Co., a pharmaceutical company focused on women's health. The chart reflects the value of its drug and contraceptive manufacturing plants, as well as its portfolio of established brands. The dynamics show how the company manages its manufacturing and product heritage.
OGN - Share of the company's book capitalization Organon Co. within the market segment - Pharma women
Organon's facilities include manufacturing facilities for a wide range of medications, with a particular focus on women's health. The chart shows the company's share of pharmaceutical production capacity, reflecting its heritage and current scale as a major manufacturer with global distribution.
Market segment balance sheet capitalization - Pharma women
Organon & Co. is a global pharmaceutical company focused on women's health. It owns a vast network of manufacturing facilities, making it very capital-intensive. Is such manufacturing capacity the norm for the pharmaceutical industry? The chart below shows the total material weight of the entire sector.
Book value of all companies included in the broad market index - GURU.Markets
Organon & Co.'s balance sheet includes a portfolio of over 60 medications and products focused on women's health, as well as manufacturing facilities. The company's assets represent capital focused on this important and often undervalued area of medicine. The chart illustrates its scale in this niche.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Organon Co.
Organon, a spinoff from Merck, focuses on women's health and biosimilars. Its balance sheet includes manufacturing assets and rights to established drugs. Its market valuation reflects the stable cash flows from these products, but also the risk of their obsolescence. The chart shows how the market values this portfolio of mature pharmaceutical assets.
Market to book capitalization ratio in a market segment - Pharma women
Organon & Co. is a pharmaceutical company specializing in women's health and biosimilars. The company owns a portfolio of established drugs. The chart shows how the market assesses this portfolio's ability to generate stable cash flow in the face of patent expirations and competition.
Market to book capitalization ratio for the market as a whole
Organon & Co. is a pharmaceutical company focused on women's health and also owns a portfolio of established drugs. The chart shows how the market values this unique business model. Its value is a combination of stable cash flows from established drugs and growth potential in the women's health niche, which determines its valuation relative to its assets.
Debts of the company, segment and market as a whole
OGN - Company debts Organon Co.
Organon is a global pharmaceutical company focused on women's health. The company's debt load may reflect its strategy of acquiring new drugs, investing in marketing existing brands, and streamlining its operating structure following its spinoff from Merck. This chart illustrates how the company is building its independent future.
Market segment debts - Pharma women
Organon & Co. is a global pharmaceutical company focused on women's health. Their portfolio includes both established drugs and new developments. This chart shows common financial metrics for the pharmaceutical industry, which can be used to analyze how Organon balances revenue from existing products with investments in the future of its portfolio.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Organon Co.
Organon was spun off from Merck and focused on women's health and biosimilars. The company needs to invest in promoting existing products and developing new ones. This chart shows its initial debt load after the spinoff and how it plans to finance its future growth as an independent pharmaceutical company.
Market segment debt to market segment book capitalization - Pharma women
Organon & Co. is a pharmaceutical company focused on women's health and a portfolio of proven drugs. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It helps assess how the company uses debt to develop its niche and support its existing products.
Debt to book value of all companies in the market
Organon & Co., focused on women's health, operates in the stable pharmaceutical sector. This chart compares its debt to the overall book value of the economy. It helps assess the company's financial conservatism and how its niche strategy compares to overall macroeconomic trends.
P/E of the company, segment and market as a whole
P/E - Organon Co.
This chart for Organon & Co., a pharmaceutical company focused on women's health, shows its market valuation. For a company with a portfolio of established drugs, this metric reflects investor expectations regarding the stability of its cash flows and its ability to develop new products in its niche.
P/E of the market segment - Pharma women
This chart shows the average valuation for the pharmaceutical sector, particularly for companies with a mature product portfolio, like Organon. It reflects how investors generally value stable, but perhaps slower-growing, businesses. It provides a benchmark for understanding whether Organon is valued in line with its peers.
P/E of the market as a whole
Organon & Co. is a global pharmaceutical company focused on women's health and a portfolio of proven drugs and biosimilars. The company occupies a unique niche in healthcare. This chart provides insight into how the market values pharmaceutical companies with stable cash flow and a clear focus.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Organon Co.
Organon & Co. is a pharmaceutical company focused on women's health and boasts a portfolio of established brands. This chart shows how the market estimates future revenue, weighing the growth potential in the women's health niche against the risk of declining sales of older drugs due to generic competition.
%20P%2FE%20Organon%20Co.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Organon-Co.&v=1772513611111 "Chart of the company's future (projected) P/E Organon Co.")
Future (projected) P/E of the market segment - Pharma women
Organon & Co. is a global pharmaceutical company focused on women's health. It offers a broad portfolio of contraception and fertility products, as well as a division for biosimilars and established brands. This chart reflects average expectations for the pharmaceutical industry as a whole, allowing us to assess Organon's position in its specialized and important niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20women&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-women&v=1772513611134 "Future (projected) P/E graph of the market segment - Pharma women")
Future (projected) P/E of the market as a whole
Organon & Co. was spun out of Merck and focuses on women's health, biosimilars, and established brands. It's a business with slower but stable growth. Amid volatile market forecasts, Organon offers predictability based on a portfolio of established and proven drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513611140 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Organon Co.
Organon & Co. is a global pharmaceutical company specializing in women's health, biosimilars, and established brands. The company's revenue is generated through sales of a diversified product portfolio. This chart shows how stable demand for proven products and a focus on the women's health niche drive robust financial results.
Profit of companies in the market segment - Pharma women
Organon & Co. is a global pharmaceutical company focused on women's health, with a portfolio of well-known blockbuster drugs and biosimilars. This chart reflects the profitability of its segment. The unique combination of a growing women's health niche and stable revenue from established products creates an interesting profile that influences overall profitability.
Overall market profit
Organon & Co. is a pharmaceutical company focused on women's health. Demand for its products, including contraceptives and fertility treatments, is driven by demographic and social trends rather than short-term economic cycles. This chart illustrates the overall market dynamics against which Organon operates in its stable and important niche.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Organon Co.
Organon & Co. is a pharmaceutical company focused on women's health, also owning a portfolio of well-known biosimilars and established brands. This chart reflects analyst revenue expectations, which depend on sales in these three segments. It demonstrates the market's confidence in the growth potential of the women's health niche and the stability of revenue from other products.
%20profit%20of%20the%20company%20Organon%20Co.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Organon-Co.&v=1772513611230 "Graph of future (projected) profit of the company Organon Co.")
Future (predicted) profit of companies in the market segment - Pharma women
Organon & Co. is a global pharmaceutical company focused on women's health and a portfolio of proven drugs and biosimilars. This chart shows profitability forecasts for the women's health sector. It reflects expectations for increased attention to this underserved area of medicine and revenue stability from legacy brands.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20women&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-women&v=1772513611241 "Graph of future (predicted) profits of companies in a market segment - Pharma women")
Future (predicted) profit of the market as a whole
Organon & Co. is a pharmaceutical company focused on women's health. Demand for its products, including contraceptives and fertility treatments, is stable. However, the overall profit forecast reflected here impacts public and private healthcare spending. Economic growth ensures stable funding for programs supporting women's health.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513611243 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Organon Co.
Organon & Co. is a pharmaceutical company focused on women's health and the production of established products. Organon's P/S reflects the market's perception of its ability to generate stable cash flow from mature products, allowing it to invest in new developments and pay dividends.
P/S market segment - Pharma women
Organon & Co. is a pharmaceutical company focused on women's health, with a portfolio of established brands and biosimilars. Their diversified revenue ensures stability. This chart helps understand how investors view their unique niche in women's health and their ability to generate cash flow from established products.
P/S of the market as a whole
Organon & Co. is a pharmaceutical company focused on women's health and owns a portfolio of established pharmaceutical brands. Revenue is generated by stable demand for its products. This chart illustrates the average revenue estimate, providing insight into how the market values predictable revenue from a diversified pharmaceutical portfolio.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Organon Co.
Organon & Co. is a pharmaceutical company formed after the spin-off from Merck, focusing on women's health and biosimilars. This chart shows how the market estimates future revenue, taking into account the stable sales of established women's health brands and the growth potential of the biosimilar portfolio, which competes with expensive originals.
%20P%2FS%20Organon%20Co.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Organon-Co.&v=1772513611348 "The graph of the company's future (projected) P/S Organon Co.")
Future (projected) P/S of the market segment - Pharma women
Organon & Co. is a global pharmaceutical company focused on women's health, with a portfolio of biosimilars and proven drugs. This chart shows how the market views the company's future sales compared to other pharmaceutical companies. It reflects investors' confidence in its strategy and growth potential in the women's health niche.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20women&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-women&v=1772513611361 "Future (projected) P/S market segment graph - Pharma women")
Future (projected) P/S of the market as a whole
Organon & Co. is a pharmaceutical company focused on women's health and boasts a portfolio of established brands. It occupies an important yet often overlooked niche in healthcare. This chart shows overall revenue projections, and Organon illustrates how specialized companies can find stable sources of growth by addressing specific market needs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513611383 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Organon Co.
Organon & Co. is a global pharmaceutical company focused on women's health, also owning a portfolio of well-known branded drugs in other areas and biosimilars. This chart shows the sales revenue of this diversified portfolio of drugs. Growth depends on demand for women's health products and stable sales of other drugs.
Sales of companies in the market segment - Pharma women
Organon & Co. is a pharmaceutical company focused on women's health, biosimilars, and established pharmaceuticals. This chart clearly shows the contribution of each of these three segments to overall revenue. Investors can assess which segment is the company's primary focus and how diversified its product portfolio is.
Overall market sales
Organon & Co. is a pharmaceutical company focused on women's health, focusing on established brands and biosimilars. Demand for its contraception and fertility treatment products is driven by demographic and social trends rather than economic cycles. This dynamic is less significant for Organon than for companies with more cyclical businesses.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Organon Co.
Organon & Co. is a pharmaceutical company focused on women's health and boasts a portfolio of established brands. Its revenue forecast is driven by sales of contraceptives, fertility drugs, and biosimilars. This chart shows analysts' growth expectations for these key therapeutic areas.
%20sales%20of%20the%20company%20Organon%20Co.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Organon-Co.&v=1772513611427 "Schedule of future (projected) sales of the company Organon Co.")
Future (projected) sales of companies in the market segment - Pharma women
Organon & Co. is a pharmaceutical company focused on women's health. This chart displays projected revenue for this specialized segment. It allows us to assess whether analysts see growth potential in this important, yet often undervalued, market, which is critical to the commercial outlook of Organon's product portfolio.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20women&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-women&v=1772513611442 "Schedule of future (projected) sales of companies in the market segment - Pharma women")
Future (projected) sales of the market as a whole
Organon & Co. is a pharmaceutical company focused on women's health, focusing on established brands and biosimilars. Demand for its women's health products is stable. However, the overall economic situation, shown in the chart, may impact pricing pressure from state healthcare systems and sales of established brands that compete with generics.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513611459 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Organon Co.
Organon & Co. is a pharmaceutical company focused on women's health and a portfolio of well-known drugs. This chart shows a financial model based on stable cash flows. The company's profitability is supported by sales of established brands, which allows it to finance the development of new products in its niche.
Market segment marginality - Pharma women
Organon & Co. is a global pharmaceutical company focused on women's health and a portfolio of proven products. This metric reflects the effectiveness of its business strategy. Stable profitability demonstrates a strong position in its niche and sustainable cash flow from mature products.
Market marginality as a whole
Organon & Co. is a pharmaceutical company focused on women's health and a portfolio of established brands with expired patents. Its strategy is stable cash flow rather than chasing blockbusters. This overall profitability chart, full of ups and downs, highlights the appeal of Organon's predictable and less risky business model.
Employees in the company, segment and market as a whole
Number of employees in the company Organon Co.
Organon & Co. is a global pharmaceutical company focused on women's health. Its staff includes both researchers and a large commercial team advancing its portfolio of established drugs. This chart illustrates the scale of its global operations and its efforts to establish leadership in its therapeutic niche.
Share of the company's employees Organon Co. within the market segment - Pharma women
Organon & Co. is a global pharmaceutical company spun out of Merck & Co., focusing on women's health. This chart illustrates its unique mission and scale. It reflects the significant number of researchers and commercial specialists working on developing and marketing medicines for women that Organon brings together.
Number of employees in the market segment - Pharma women
Organon & Co. is a global pharmaceutical company focused on women's health. This chart illustrates employment in the pharmaceutical sector specializing in women's health. Growth in this niche reflects increasing attention and investment in historically underexplored areas, creating significant growth opportunities for Organon.
Number of employees in the market as a whole
Organon & Co. is a global pharmaceutical company focused on women's health. Stable demand for its products, from contraceptives to osteoporosis treatments, ensures sustainable employment. The company represents a vital segment of healthcare, creating jobs and improving the quality of life for millions of people.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Organon Co. (OGN)
Organon & Co. is a pharmaceutical company spun out of Merck, focusing on women's health and biosimilars. Their value is based on their portfolio of existing, revenue-generating drugs. This chart shows that even for a company with established products, pharmaceuticals remains an industry with a high market capitalization per employee due to the value of brands and patents.
%20of%20the%20company%20Organon%20Co.%20(OGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Organon-Co.-OGN&v=1772513611732 "Chart of market capitalization per employee (in thousands of dollars) of the company Organon Co. (OGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma women
Organon & Co. (spinned off from Merck) focuses on women's health and also owns a portfolio of legacy brand-name drugs and biosimilars. It's a hybrid model. This chart shows the industry average. It helps assess how the market values this combination of niche R&D and a stable but ungrowing portfolio per employee.
%20by%20market%20segment%20-%20Pharma%20women&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-women&v=1772513611752 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma women")
Market capitalization per employee (in thousands of dollars) for the overall market
Organon is a global pharmaceutical company specializing in women's health. The company owns a portfolio of established drugs and is responsible for their marketing and distribution. This chart provides an overview of how the market perceives the team's ability to effectively manage this portfolio and generate stable cash flow.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513611780 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Organon Co. (OGN)
Organon & Co. (a spinoff from Merck) is a pharmaceutical company focused on women's health and a portfolio of legacy branded drugs (biosimilars). This chart shows how effectively the company is milking its legacy but stable drugs to fund women's health R&D, leveraging its sales force.
%20Chart%20Organon%20Co.%20(OGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Organon-Co.-OGN&v=1772513611875 "Company Profit Per Employee (in thousands of dollars) Chart Organon Co. (OGN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma women
Organon (a spinoff from Merck) is a pharmaceutical company focused on women's health and legacy drugs that have lost their patents. This chart shows the benchmark for the Pharmaceutical Sector. In this legacy sector, the benchmark is moderate. Profit per employee is generated not by R&D, but by the efficiency of the plants producing these legacy but stable drugs.
%20in%20the%20market%20segment%20-%20Pharma%20women&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-women&v=1772513611916 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma women")
Profit per employee (in thousands of dollars) for the market as a whole
Organon (a spinoff from Merck) is a pharmaceutical company focused on women's health (contraception). They also manage a portfolio of legacy brand-name drugs. This chart, showing the market average profitability per employee, helps us understand how effective this diversified model ("women's health + legacy") is.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513611925 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Organon Co. (OGN)
Organon & Co., a pharmaceutical company focused on women's health, shows the performance of its drug portfolio in this chart. Revenue per employee is driven by sales of established brands and the successful launch of new products. This increase indicates a strong commercial position and demand for its medications.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Organon-Co.-OGN&v=1772513611942 "Sales chart per company employee Organon Co. (OGN)")
Sales per employee in the market segment - Pharma women
Organon & Co. is a global pharmaceutical company focused on women's health, biosimilars, and mature drugs. This chart shows the average revenue per employee in the segment. It helps evaluate how effectively Organon's commercial and manufacturing teams manage their diversified portfolio compared to competitors.
Sales per employee for the market as a whole
Organon & Co. (OGN) is a pharmaceutical company spun off from Merck, focusing on women's health and legacy drugs. This metric reflects how effectively the company manages its portfolio. It needs to generate maximum revenue from stable but less-growing drugs to fund R&D in new areas without inflating its staff.
Short shares by company, segment and market as a whole
Shares shorted by company Organon Co. (OGN)
Organon & Co. was spun off from Merck and focused on women's health (contraceptives) and "legacy" brand-name drugs (biosimilars). This chart highlights concerns about this strategy. Bears are betting that revenues from older drugs will decline too quickly and competition in the biosimilar segment will be too fierce.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Organon-Co.-OGN&v=1772513611970 "Short Shares Chart for the Company Organon Co. (OGN)")
Shares shorted by market segment - Pharma women
Organon & Co. (OGN) spun off from Merck, focusing on women's health, biosimilars, and legacy drugs. It's a low-growth business with stable pipeline. This chart highlights the pessimism in the pharmaceutical sector. The rise in short positions across the industry may reflect concerns that patent cliffs on key OGN drugs or competition from biosimilars will hurt revenue.
Shares shorted by the overall market
Organon & Co. is a unique pharmaceutical company focused on women's health, from contraception to fertility treatments, as well as biosimilars. This sector is often considered "defensive." This chart shows the overall level of market pessimism. During periods of fear (when the indicator rises), investors often seek refuge in stocks with stable demand. This chart helps assess whether this defensive theory holds true for OGN.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Organon Co. (OGN)
Organon, spun off from Merck, focuses on women's health and a portfolio of established brands/biosimilars. The business generates cash, but growth is limited. A chart above 70 may reflect revenue stability. A range below 30 may reflect concerns about generic competition or debt issues.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Organon-Co.-OGN&v=1772513612020 "RSI 14 indicator chart for the company's stock Organon Co. (OGN)")
RSI 14 Market Segment - Pharma women
Organon & Co. is a global pharmaceutical company spun out of Merck. It focuses on two areas: women's health (contraceptives) and established brands (off-patent medications). This chart shows the overall sentiment in the women's health pharmaceutical sector. It helps assess how investors view this niche compared to the rest of the pharmaceutical industry.
RSI 14 for the overall market
Organon, a pharmaceutical company focused on women's health, has two important factors. Demand for its products (contraceptives) is stable during both panic and euphoria. However, like any company, during periods of market panic, it can face a decline in the value of its investment assets and pressure on its valuation.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OGN (Organon Co.)
Organon & Co. (OGN) is a global pharmaceutical company spun out of Merck. It focuses on women's health (contraceptives), as well as biosimilars and a portfolio of legacy products. The chart shows the average target price. It reflects analysts' assessment of Organon's ability to stabilize revenue from legacy brands and grow the women's health segment.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OGN-Organon-Co.&v=1772513612066 "A chart showing analyst consensus forecasts for the expected stock price. OGN (Organon Co.)")
The difference between the consensus estimate and the actual stock price OGN (Organon Co.)
Organon & Co. is a pharmaceutical company formed from Merck assets, with a unique focus on women's health (contraception) and biosimilars. This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the consensus price forecast and the current price, reflecting confidence in this niche strategy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OGN-Organon-Co.&v=1772513612076 "A chart showing the difference between the consensus forecast and the actual stock price. OGN (Organon Co.)")
Analyst consensus forecast for stock prices by market segment - Pharma women
Organon is a company focused on women's health (contraceptives, IVF) and biosimilars (analogs of complex drugs). It is a former division of Merck. This chart shows analysts' overall expectations for the entire women's pharmaceutical sector. It reflects whether experts believe in the growth of this historically undervalued market.
Analysts' consensus forecast for the overall market share price
Organon (OGN) is a Merck spinoff focused on women's health (contraception) and legacy medications (biosimilars). This chart, reflecting expert expectations, influences them. During a recession (pessimism), their protective products are stable, but healthcare budgets are being cut, putting pressure on prices.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Organon Co.
Organon is a Merck spinoff with a unique focus on women's health (leading contraception) and biosimilars (generics of biologics). This chart is a summary indicator of their complex strategy. It aggregates the growth rates of their key women's franchises and biosimilars, weighing them against the inevitable decline in revenue from their legacy portfolio.
AKIMA Market Segment Index - Pharma women
Organon (OGN) is a pharmaceutical company (spinned out of Merck) focused on two things: women's health (contraceptives like Nexplanon) and stable cash flow from a portfolio of legacy brands. This composite metric evaluates companies. The graph shows the average value for the segment. This benchmark: how does OGN's hybrid (stability + niche) model differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Organon (spinned off from Merck) is a pharmaceutical company focused on women's health (contraceptives) and biosimilars (generics). It's a stable (defensive) but mature business. This chart, reflecting the market average, provides a macro backdrop. It helps assess how Organon fits within the overall macroeconomic picture affecting the healthcare sector.
